cholestyramine resin has been researched along with probucol in 75 studies
| Studies (cholestyramine resin) | Trials (cholestyramine resin) | Recent Studies (post-2010) (cholestyramine resin) | Studies (probucol) | Trials (probucol) | Recent Studies (post-2010) (probucol) |
|---|---|---|---|---|---|
| 2,669 | 342 | 190 | 1,488 | 174 | 317 |
| Protein | Taxonomy | cholestyramine resin (IC50) | probucol (IC50) |
|---|---|---|---|
| NAD-dependent protein deacylase sirtuin-5, mitochondrial | Homo sapiens (human) | 1.6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 42 (56.00) | 18.7374 |
| 1990's | 29 (38.67) | 18.2507 |
| 2000's | 2 (2.67) | 29.6817 |
| 2010's | 1 (1.33) | 24.3611 |
| 2020's | 1 (1.33) | 2.80 |
| Authors | Studies |
|---|---|
| Diament, J; Forti, N; Giannini, SD | 1 |
| Martz, BL | 1 |
| Castrillo, JM; Díaz-Curiel, M; Rapado, A | 1 |
| Fleischmajer, R | 1 |
| Davison, KL; Sell, JL | 1 |
| Itakura, H | 1 |
| Makino, I | 1 |
| Arai, H; Hara, S; Ishii, K; Kita, T; Kume, N; Nagano, Y; Otani, H; Ueda, Y; Yokode, M | 1 |
| Grundy, SM | 1 |
| Mimura, K; Yukawa, S | 1 |
| Liu, K | 1 |
| D'Amico, G; Gentile, MG | 1 |
| Kurota, M; Maeda, H; Matsuda, T; Miyaho, S; Morikawa, K; Nakai, T; Oida, K; Takahashi, S; Takai, H; Tamai, T | 1 |
| Eisenberg, JM; Glick, H; Jacobson, TA; Kinosian, B; Koffer, H; Schulman, KA; Willian, MK | 1 |
| Arai, H; Ishii, K; Kawai, C; Kita, T; Kume, N; Nagano, Y; Otani, H; Ueda, Y; Yokode, M | 1 |
| Shapiro, DR; Walker, JF | 1 |
| Carlson, LA; Nilsson, J; Regnström, J; Walldius, G | 1 |
| Islami, Y; Ribeiro, LG | 1 |
| Carlson, LA; Erikson, U; Johansson, J; Kaijser, L; Lassvik, C; Mölgaard, J; Nilsson, S; Olsson, AG; Stenport, G; Walldius, G | 1 |
| Naito, HK | 1 |
| Davignon, J | 2 |
| Blum, CB; Levy, RI | 1 |
| Nikkilä, EA; Tikkanen, MJ | 1 |
| Havel, RJ; Kane, JP | 1 |
| Gotto, AM; Jones, PH; Scott, LW | 1 |
| DiPalma, JR | 1 |
| Funahashi, T; Kishino, B; Matsuzawa, Y; Yamamoto, A; Yamamura, T; Yokoyama, S | 1 |
| Bonfiglioli, D; Branchi, A; Cabrini, E; Pogliaghi, I; Sommariva, D; Tirrito, M | 1 |
| Levy, RI; Schaefer, EJ | 1 |
| Adolph, R; Glueck, CJ; Rice, V; Spitz, HB; Stein, EA | 1 |
| Bloch, CA; Botha, A; McNamara, DJ; Mendelsohn, D | 1 |
| Fumagalli, R; Paoletti, R; Sirtori, C | 1 |
| Barker, K; Carter, RC; Cassels, E; Jelfs, R; Mann, JI; Simpson, HC | 1 |
| Biso, P; Melchionda, N; Parenti, M; Pasquali, R | 1 |
| Bateson, MC | 1 |
| Mann, JI | 1 |
| Dietschy, JM; Turley, SD | 1 |
| Carter, RD; Cobbe, SM; Jones, DB; Lousley, S; Mann, JI; Simpson, HC; Slaughter, P | 1 |
| Nash, DT | 2 |
| Vesselinovitch, D; Wissler, RW | 1 |
| Kane, JP; Malloy, MJ | 1 |
| Azarnoff, DL; Saunders, RN | 1 |
| LaRosa, JC | 1 |
| Nestel, PJ | 1 |
| Boyden, TW; Totman, L | 1 |
| Samuel, P | 1 |
| Albengres, E; Choisy, H; Millart, H; Tillement, JP | 1 |
| Esmail, A; Fears, R | 1 |
| Bergstrand, L; Elinder, LS; Erikson, U; Holme, I; Johansson, J; Mölgaard, J; Nilsson, S; Olsson, AG; Walldius, G | 1 |
| Elinder, LS; Hådell, K; Holme, I; Johansson, J; Mølgaard, J; Olsson, AG; Walldius, G | 1 |
| Gotto, AM; Yeshurun, D | 1 |
| Anderson, TJ; Frei, B; Ganz, P; Meredith, IT; Selwyn, AP; Yeung, AC | 1 |
| Farmer, JA; Gotto, AM | 1 |
| Bergstrand, L; Erikson, U; Hådell, K; Johansson, J; Kaijser, L; Lassvik, C; Mölgaard, J; Nilsson, S; Olsson, AG; Walldius, G | 1 |
| Fujimori, T; Hayashi, K; Hiyoshi, H; Kimura, T; Kobayashi, H; Kogushi, M; Ohtsuka, I; Saeki, T; Tanaka, H; Yamada, T | 1 |
| Hirakoso, K; Kohno, T; Mori, T; Ohtani, A; Takashima, K; Takeyama, S | 1 |
| Ades, EW; Lawley, TJ; Pruckler, JM | 1 |
| Auwerx, J; Fruchart, JC; Staels, B; Van Tol, A | 1 |
| Boissonnat, P; de Lorgeril, M; Dureau, G; Monjaud, I; Salen, P | 1 |
| Gørbitz, C; Ose, L; Retterstøl, K; Stugaard, M | 1 |
| Kesten, S; Maurer, J; Mayne, L; Scavuzzo, M | 1 |
| Fukuzawa, S; Inagaki, M; Inoue, T; Morooka, S; Ozawa, S | 1 |
| Chin-Dusting, JP; Shaw, JA | 1 |
| Nagai, Y; Yamashita, S | 1 |
| Herbas, MS; Ishida, N; Kume, A; Shichiri, M; Suzuki, H | 1 |
| Chen, L; Chen, SC; Tsui, L; Wu, SJ; Xie, W; Xu, S; Ye, P | 1 |
17 review(s) available for cholestyramine resin and probucol
| Article | Year |
|---|---|
[Therapeutic orientation in the hyperlipidemias].
Topics: Cholestyramine Resin; Dextrothyroxine; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Neomycin; Nicotinic Acids; Oxandrolone; Probucol; Sitosterols; Triglycerides | 1979 |
Cholesterol-lowering drugs as cardioprotective agents.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Niacin; Probucol | 1992 |
[Advance in drug treatment of primary and familial hypercholesterolemia].
Topics: Animals; Cholestyramine Resin; Drugs, Chinese Herbal; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lovastatin; Panax; Plants, Medicinal; Probucol | 1991 |
Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Clinical Trials as Topic; Colestipol; Cost-Benefit Analysis; Drug Therapy, Combination; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Niacin; Probucol; Sensitivity and Specificity | 1990 |
Lipid lowering effects on cardiovascular morbidity and mortality. Clinical evidence and therapeutic guidelines.
Topics: Cholesterol; Cholestyramine Resin; Clinical Trials as Topic; Clofibrate; Coronary Disease; Follow-Up Studies; Gemfibrozil; Humans; Hypolipidemic Agents; Lipoproteins; Male; Probucol; Triglycerides | 1988 |
Reducing cardiac deaths with hypolipidemic drugs.
Topics: Cholesterol; Cholestyramine Resin; Clofibrate; Colestipol; Coronary Disease; Feeding Behavior; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lipoproteins, LDL; Niacin; Patient Education as Topic; Pentanoic Acids; Probucol | 1987 |
Treatment of hypercholesterolemia.
Topics: Animals; Cholestyramine Resin; Clofibrate; Colestipol; Cricetinae; Dogs; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Mice; Middle Aged; Neomycin; Niacin; Pentanoic Acids; Pregnancy; Probucol; Rats | 1986 |
The diagnosis and management of hyperlipidemia.
Topics: Adolescent; Adult; Child; Child, Preschool; Cholesterol; Cholestyramine Resin; Chylomicrons; Clofibrate; Colestipol; Coronary Disease; Dextrothyroxine; Dietary Fats; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hyperlipidemias; Hyperlipoproteinemia Type I; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Hyperlipoproteinemia Type IV; Hyperlipoproteinemia Type V; Lipoproteins; Lipoproteins, LDL; Neomycin; Niacin; Pentanoic Acids; Probucol; Receptors, LDL; Triglycerides | 1986 |
Pathogenesis and management of lipoprotein disorders.
Topics: Abetalipoproteinemia; Adolescent; Adult; Aged; Child; Child, Preschool; Cholestyramine Resin; Chylomicrons; Colestipol; Dietary Fats; Female; Gemfibrozil; Humans; Hyperlipoproteinemia Type I; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Hyperlipoproteinemia Type IV; Hyperlipoproteinemia Type V; Hyperlipoproteinemias; Hypobetalipoproteinemias; Hypolipoproteinemias; Infant; Infant, Newborn; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Niacin; Pentanoic Acids; Probucol; Tangier Disease | 1985 |
Hypolipidemic drugs.
Topics: Aminosalicylic Acids; Androgens; Bile Acids and Salts; Butyrates; Cellulose; Cholestyramine Resin; Clofibrate; Contraceptives, Oral; Female; Gonadal Steroid Hormones; Halofenate; Humans; Hyperlipidemias; Hypolipidemic Agents; Intestinal Absorption; Lignin; Lipid Metabolism; Lipid Mobilization; Male; Nafenopin; Neomycin; Nicotinic Acids; Oxandrolone; Probucol; Progestins; Sitosterols; Sterols; Thyroxine; Triglycerides | 1973 |
[Diagnosis and treatment of primary hyperlipidemias].
Topics: Cholesterol; Cholestyramine Resin; Clofibrate; Diagnosis, Differential; Drug Therapy, Combination; Female; Humans; Hyperlipidemia, Familial Combined; Male; Nicotinic Acids; Probucol; Triglycerides | 1982 |
Treatment of hypercholesterolemia.
Topics: Cholestyramine Resin; Colestipol; Drug Therapy, Combination; Heterozygote; Homozygote; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Neomycin; Niacin; Nicotinic Acids; Probucol; Sitosterols; Thyroxine | 1982 |
Current status of drugs used to treat hyperlipoproteinemias.
Topics: Aminosalicylic Acid; Cholestyramine Resin; Clinical Trials as Topic; Colestipol; Enzyme Induction; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Neomycin; Niacin; Nicotinic Acids; Probucol; Sitosterols | 1982 |
Hyperlipidemia: perspectives in diagnosis and treatment.
Topics: Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Coronary Disease; Diet, Fat-Restricted; Diet, Reducing; Exercise; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Niacin; Probucol; Risk; Triglycerides | 1995 |
Antihyperlipidaemic agents. Drug interactions of clinical significance.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Clofibric Acid; Colestipol; Drug Interactions; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Probucol | 1994 |
Lipids and atherosclerosis: clinical management of hypercholesterolaemia.
Topics: Arteriosclerosis; Cholestyramine Resin; Clinical Trials as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Metabolism; Niacin; Nutritional Physiological Phenomena; Probucol | 2001 |
[Treatment of high blood cholesterol in patients with coronary heart disease].
Topics: Anion Exchange Resins; Cholesterol, LDL; Cholestyramine Resin; Clinical Trials as Topic; Coronary Disease; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Primary Prevention; Probucol; Receptors, LDL; Risk Factors | 2003 |
12 trial(s) available for cholestyramine resin and probucol
| Article | Year |
|---|---|
Cholesterol-lowering drugs as cardioprotective agents.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Niacin; Probucol | 1992 |
Pharmacological and dietary treatment of lipid abnormalities in nephrotic patients.
Topics: Cholestyramine Resin; Colestipol; Food, Formulated; Gemfibrozil; Humans; Hyperlipidemias; Lipids; Lovastatin; Nephrotic Syndrome; Probucol | 1991 |
Hydroxymethylglutaryl coenzyme A reductase inhibitors as monotherapy in the treatment of hypercholesterolemia.
Topics: Bezafibrate; Cholestyramine Resin; Double-Blind Method; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lovastatin; Probucol; Randomized Controlled Trials as Topic; Simvastatin | 1990 |
Lipid lowering effects on cardiovascular morbidity and mortality. Clinical evidence and therapeutic guidelines.
Topics: Cholesterol; Cholestyramine Resin; Clinical Trials as Topic; Clofibrate; Coronary Disease; Follow-Up Studies; Gemfibrozil; Humans; Hypolipidemic Agents; Lipoproteins; Male; Probucol; Triglycerides | 1988 |
Development of femoral atherosclerosis in hypercholesterolemic patients during treatment with cholestyramine and probucol/placebo: Probucol Quantitative Regression Swedish Trial (PQRST): a status report.
Topics: Arteriosclerosis; Cholestyramine Resin; Clinical Trials as Topic; Combined Modality Therapy; Drug Therapy, Combination; Female; Femoral Artery; Humans; Hypercholesterolemia; Lipids; Male; Phenols; Placebos; Probucol; Random Allocation; Remission Induction; Research Design; Sweden | 1988 |
Probucol and cholestyramine combination in the treatment of severe hypercholesterolemia.
Topics: Adult; Aged; Blood Pressure; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Female; Heart Rate; Humans; Hypercholesterolemia; Lipoproteins; Lipoproteins, VLDL; Male; Middle Aged; Phenols; Probucol; Random Allocation; Triglycerides | 1986 |
A comparison of cholestyramine and probucol in the treatment of familial hypercholesterolaemia.
Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Cholestyramine Resin; Clinical Trials as Topic; Dietary Fats; Humans; Hyperlipoproteinemia Type II; Lipoproteins, VLDL; Middle Aged; Phenols; Probucol; Triglycerides | 1984 |
Current status of drugs used to treat hyperlipoproteinemias.
Topics: Aminosalicylic Acid; Cholestyramine Resin; Clinical Trials as Topic; Colestipol; Enzyme Induction; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Neomycin; Niacin; Nicotinic Acids; Probucol; Sitosterols | 1982 |
Lowering of HDL2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia. A Probucol Quantitative Regression Swedish Trial (PQRST) Report.
Topics: Apolipoprotein A-I; Arteriosclerosis; Cholesterol, HDL; Cholestyramine Resin; Female; Femoral Artery; Humans; Hypercholesterolemia; Male; Middle Aged; Probucol; Radiography; Regression Analysis; Sweden | 1995 |
Probucol treatment decreases serum concentrations of diet-derived antioxidants.
Topics: Antioxidants; Cholestyramine Resin; Diet; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Patient Compliance; Probucol; Regression Analysis; Sweden | 1995 |
The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion.
Topics: Acetylcholine; Anticholesteremic Agents; Antioxidants; Cholestyramine Resin; Coronary Artery Disease; Endothelium, Vascular; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Probucol; Regression Analysis; Vasoconstriction; Vasodilation | 1995 |
The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST).
Topics: Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Double-Blind Method; Female; Femoral Artery; Humans; Hypercholesterolemia; Image Processing, Computer-Assisted; Male; Middle Aged; Probucol; Radiography | 1994 |
49 other study(ies) available for cholestyramine resin and probucol
| Article | Year |
|---|---|
Drug management of hypercholesterolemia.
Topics: Cholestyramine Resin; Clofibrate; Colestipol; Dextrothyroxine; Humans; Hypercholesterolemia; Nicotinic Acids; Probucol; Sitosterols | 1979 |
Use of diet and probucol.
Topics: Child; Cholestyramine Resin; Female; Humans; Hypercholesterolemia; Phenols; Probucol | 1979 |
Hypolipidemic drugs.
Topics: Cholestyramine Resin; Clofibrate; Colestipol; Dextrothyroxine; Humans; Hyperlipidemias; Lipoproteins; Nicotinic Acids; Probucol | 1978 |
Dieldrin-14C elimination from chickens.
Topics: Animals; Anion Exchange Resins; Charcoal; Chickens; Cholestyramine Resin; Dieldrin; Gallbladder; Probucol; Starvation | 1978 |
[Treatment of hyperlipidemia].
Topics: Blood Component Removal; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Coronary Disease; Dietary Fiber; Energy Intake; Female; Humans; Hyperlipidemias; Male; Niceritrol; Pravastatin; Probucol | 1992 |
[Diagnosis and treatment of familial hypercholesterolemia].
Topics: Adult; Blood Component Removal; Cholesterol, LDL; Cholestyramine Resin; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Male; Middle Aged; Probucol; Reference Standards | 1992 |
The role of oxidized lipoproteins in the pathogenesis of atherosclerosis.
Topics: Animals; Apolipoproteins B; Cholesterol Esters; Cholestyramine Resin; Coronary Artery Disease; Lipoproteins; Lipoproteins, HDL; Lipoproteins, LDL; Macrophages; Mice; Oxidation-Reduction; Pravastatin; Probucol; Rabbits; Receptors, LDL; RNA, Messenger | 1992 |
[Clinical study of lipid metabolism disorders (discussion)].
Topics: Arteriosclerosis; Cholestyramine Resin; Diet; Humans; Hyperlipidemias; Lipid Metabolism; Lovastatin; Probucol; Risk Factors | 1992 |
[Hyperlipidemia and drug treatment].
Topics: Arteriosclerosis; Carnitine; Cholestyramine Resin; Glomerulonephritis; Humans; Hyperlipidemias; Kidney Failure, Chronic; Niceritrol; Pantetheine; Pravastatin; Probucol; Vitamin E | 1991 |
Choice of cholesterol-lowering drugs.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Clofibrate; Colestipol; Fish Oils; Gemfibrozil; Humans; Lovastatin; Neomycin; Niacin; Probucol | 1991 |
[A case of familial hypercholesterolemia associated with nephrotic syndrome].
Topics: Cholestyramine Resin; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Middle Aged; Naphthalenes; Nephrotic Syndrome; Pravastatin; Prednisolone; Probucol | 1990 |
Lipoproteins and atherosclerosis.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Cholesterol Esters; Cholestyramine Resin; Disease Models, Animal; Foam Cells; Heptanoic Acids; Hyperlipidemia, Familial Combined; Lipoproteins, LDL; Liver; Macrophages; Mice; Naphthalenes; Pravastatin; Probucol; Rabbits; Receptors, Cell Surface; Receptors, Lipoprotein | 1990 |
Effect of probucol treatment on the susceptibility of low density lipoprotein isolated from hypercholesterolemic patients to become oxidatively modified in vitro.
Topics: Aged; Cells, Cultured; Cholesterol; Cholestyramine Resin; Fatty Acids; Female; Food, Formulated; Humans; Hypercholesterolemia; Lipoproteins, LDL; Macrophages; Male; Middle Aged; Oxidation-Reduction; Phenols; Probucol; Receptors, LDL | 1990 |
Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel.
Topics: Adult; Aged; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Colestipol; Coronary Disease; Dietary Fats; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Male; Middle Aged; Niacin; Patient Compliance; Pentanoic Acids; Probucol; Risk Factors | 1988 |
Medical management of hyperlipidemia and the role of probucol.
Topics: Adult; Arteriosclerosis; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Female; Gemfibrozil; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Middle Aged; Niacin; Pentanoic Acids; Phenols; Probucol; Risk | 1986 |
Rational drug therapy of the hyperlipoproteinemias, Part II.
Topics: Cholestyramine Resin; Clofibrate; Colestipol; Dextrothyroxine; Female; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Neomycin; Niacin; Pentanoic Acids; Probucol | 1986 |
Current pharmacologic treatment of elevated serum cholesterol.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Drug Tolerance; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Naphthalenes; Neomycin; Niacin; Pentanoic Acids; Probucol; Simvastatin; Triglycerides | 1987 |
Lovastatin: cholesterol-lowering agent.
Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Humans; Hypercholesterolemia; Lovastatin; Probucol | 1987 |
Effects of probucol on xanthomata regression in familial hypercholesterolemia.
Topics: Achilles Tendon; Adolescent; Adult; Aged; Anticholesteremic Agents; Child; Child, Preschool; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Drug Therapy, Combination; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Naphthalenes; Phenols; Plasmapheresis; Probucol; Xanthomatosis | 1986 |
Addition to labeling of cholestyramine.
Topics: Cholestyramine Resin; Clofibrate; Diet Therapy; Drug Labeling; Gemfibrozil; Humans; Hypolipidemic Agents; Niacin; Pentanoic Acids; Probucol; Thyroxine; United States; United States Food and Drug Administration | 1985 |
Lipid-lowering drugs.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Clofibrate; Colestipol; Dextrothyroxine; Gemfibrozil; Humans; Hypolipidemic Agents; Lipoproteins; Neomycin; Niacin; Pentanoic Acids; Probucol; Triglycerides | 1985 |
Nonprogression of coronary artery atherosclerosis in homozygous familial hypercholesterolemia after 31 months of repetitive plasma exchange.
Topics: Achilles Tendon; Adult; Angiography; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Coronary Disease; Echocardiography; Female; Homozygote; Humans; Hyperlipoproteinemia Type II; Plasma Exchange; Probucol; Xanthomatosis | 1986 |
Sterol synthesis in vitro in freshly isolated blood mononuclear leukocytes from familial hypercholesterolemic patients treated with probucol.
Topics: Cholesterol; Cholestyramine Resin; Female; Humans; Hyperlipoproteinemia Type II; Male; Monocytes; Phenols; Probucol; Sterols | 1985 |
Probucol in patients resistant to the lipid-lowering effects of cholestyramine.
Topics: Adult; Cholestyramine Resin; Humans; Hyperlipoproteinemia Type II; Middle Aged; Phenols; Probucol | 1981 |
Combined effects of probucol and cholestyramine in familial type II hyperlipoproteinaemia.
Topics: Cholestyramine Resin; Drug Therapy, Combination; Female; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Phenols; Probucol | 1981 |
Probucol with cholestyramine.
Topics: Cholestyramine Resin; Drug Synergism; Humans; Hypercholesterolemia; Phenols; Probucol | 1981 |
Probucol, cholestyramine, and serum cholesterol.
Topics: Cholesterol; Cholestyramine Resin; Drug Synergism; Humans; Phenols; Probucol | 1981 |
Effects of clofibrate, cholestyramine, zanchol, probucol, and AOMA feeding on hepatic and intestinal cholesterol metabolism and on biliary lipid secretion in the rat.
Topics: Animals; Anticholesteremic Agents; Bile; Butyrates; Cholesterol; Cholestyramine Resin; Clofibrate; Female; Fluorenes; Intestines; Lipid Metabolism; Liver; Polymers; Probucol; Rats; Succinates | 1980 |
Gemfibrozil in combination with other drugs for severe hyperlipidemia. Preliminary study comprising four cases.
Topics: Adult; Cholesterol; Cholestyramine Resin; Colestipol; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hyperlipidemias; Lipoproteins, HDL; Male; Middle Aged; Niacin; Pentanoic Acids; Probucol; Triglycerides; Valerates | 1983 |
Hyperlipidemia: reducing the chances of cardiovascular disease.
Topics: Cholesterol; Cholestyramine Resin; Clofibrate; Coronary Disease; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Pentanoic Acids; Probucol; Triglycerides | 1984 |
Combined effects of cholestyramine and probucol on regression of atherosclerosis in rhesus monkey aortas.
Topics: Animals; Aorta; Aortic Diseases; Arteriosclerosis; Cholestyramine Resin; Diet, Atherogenic; Drug Therapy, Combination; Lipids; Macaca mulatta; Male; Phenols; Probucol | 1983 |
The mechanism of action of lipid-lowering drugs.
Topics: Cholestyramine Resin; Chylomicrons; Clofibrate; Fatty Acids; Hypolipidemic Agents; Lipid Metabolism; Lipolysis; Lipoprotein Lipase; Lipoproteins; Nicotinic Acids; Probucol | 1982 |
Cholestyramine and probucol synergism.
Topics: Adult; Cholestyramine Resin; Drug Synergism; Humans; Male; Phenols; Probucol | 1982 |
Synergistic effects of probucol and cholestyramine to lower serum cholesterol.
Topics: Adult; Aged; Cholesterol; Cholestyramine Resin; Dietary Fats; Drug Synergism; Drug Therapy, Combination; Humans; Hypercholesterolemia; Male; Middle Aged; Phenols; Probucol | 1981 |
Lipid-lowering drugs.
Topics: Cholestyramine Resin; Clofibrate; Colestipol; Humans; Hypolipidemic Agents; Neomycin; Nicotinic Acids; Probucol | 1980 |
Drug treatment of hyperlipidemia.
Topics: Adolescent; Adult; Child; Cholesterol; Cholestyramine Resin; Clofibrate; Colestipol; Humans; Hyperlipidemias; Middle Aged; Neomycin; Nicotinic Acids; Probucol | 1980 |
[Hypolipidaemic agents (author's transl)].
Topics: Animals; Chemical Phenomena; Chemistry; Cholesterol; Cholestyramine Resin; Clofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Nicotinic Acids; Probucol | 1980 |
The regulation of cholesterol metabolism in Ehrlich ascites tumour cells by dietary cholesterol, cholestyramine and probucol.
Topics: Animals; Carcinoma, Ehrlich Tumor; Cholesterol; Cholesterol, Dietary; Cholestyramine Resin; Mice; Phenols; Probucol; Triglycerides | 1980 |
Effect of the acyl-CoA:cholesterol acyltransferase inhibitor, E5324, on experimental atherosclerosis in rabbits.
Topics: Anilides; Animals; Aorta, Thoracic; Arteriosclerosis; Cholestyramine Resin; Dose-Response Relationship, Drug; Lipid Metabolism; Liver; Male; Phenylurea Compounds; Probucol; Rabbits; Sterol O-Acyltransferase; Tunica Intima; Tunica Media | 1994 |
The hypocholesterolemic action of TA-7552 and its effects on cholesterol metabolism in the rat.
Topics: Animals; Bezafibrate; Bile Acids and Salts; Cholestanol; Cholesterol; Cholesterol, Dietary; Cholesterol, HDL; Cholestyramine Resin; Chromatography, Gas; Feces; Liver; Naphthols; Probucol; Rats; Rats, Sprague-Dawley | 1994 |
Use of a human microvascular endothelial cell line as a model system to evaluate cholesterol uptake.
Topics: Biological Transport; Cells, Cultured; Cholesterol; Cholestyramine Resin; Clofibrate; Endothelium, Vascular; Gemfibrozil; Humans; Models, Biological; Probucol; Tritium | 1993 |
Choice of cholesterol-lowering drugs.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Clofibrate; Colestipol; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Niacin; Probucol | 1993 |
Effects of hypolipidemic drugs on the expression of genes involved in high density lipoprotein metabolism in the rat.
Topics: Actins; Animals; Apolipoproteins; Cholestyramine Resin; Clofibrate; Fenofibrate; Gene Expression Regulation; Hypolipidemic Agents; Intestinal Mucosa; Lipid Metabolism; Lipoproteins, HDL; Liver; Lovastatin; Male; Niacin; Probucol; Rats; Rats, Wistar; Simvastatin | 1996 |
Fenofibrate, probucol, and other lipid-lowering treatments in heart transplant recipients.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Cyclosporine; Drug Interactions; Fenofibrate; Gemfibrozil; Heart Transplantation; Humans; Hypolipidemic Agents; Immunosuppressive Agents; Lovastatin; Probucol; Simvastatin | 1996 |
Results of intensive long-term treatment of familial hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atrial Natriuretic Factor; Cholesterol; Cholestyramine Resin; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Probucol; Quality of Life; Treatment Outcome | 1996 |
Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation.
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Cholestyramine Resin; Echocardiography; Female; Follow-Up Studies; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemias; Hypertriglyceridemia; Hypolipidemic Agents; Immunosuppressive Agents; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Lung Transplantation; Male; Middle Aged; Myocardial Ischemia; Probucol; Radionuclide Angiography; Retrospective Studies; Triglycerides; Ventricular Dysfunction, Left; Ventricular Function, Left | 1997 |
Secondary prevention with lipid lowering therapy in familial hypercholesterolemia: a correlation between new evolution of stenotic lesion and achieved cholesterol levels after revascularization procedures.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cholestyramine Resin; Coronary Artery Bypass; Coronary Artery Disease; Coronary Disease; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Male; Middle Aged; Probucol | 1999 |
Effect of anti-hyperlipidemia drugs on the alpha-tocopherol concentration and their potential for murine malaria infection.
Topics: alpha-Tocopherol; Animals; Anticholesteremic Agents; Antimalarials; Berberine; Cholestyramine Resin; Ezetimibe; Female; Malaria; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Parasitemia; Plasmodium yoelii; Probucol; Specific Pathogen-Free Organisms; Vitamin E Deficiency | 2016 |
Adverse drug reactions of non-statin antihyperlipidaemic drugs in China from 1989 to 2019: a national database analysis.
Topics: Cholestyramine Resin; Drug-Related Side Effects and Adverse Reactions; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Niacin; Probucol | 2023 |